Q4 2024 13F Holders as of 12/31/2024
-
Type / Class
-
Equity / Common Stock
-
Shares outstanding
-
49.6M
-
Number of holders
-
111
-
Total 13F shares, excl. options
-
29.4M
-
Shares change
-
-3.13M
-
Total reported value, excl. options
-
$89.6M
-
Value change
-
-$7.8M
-
Put/Call ratio
-
0.12
-
Number of buys
-
63
-
Number of sells
-
-35
-
Price
-
$3.05
Significant Holders of PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) as of Q4 2024
131 filings reported holding PBYI - PUMA BIOTECHNOLOGY, INC. - Common Stock as of Q4 2024.
PUMA BIOTECHNOLOGY, INC. - Common Stock (PBYI) has 111 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 29.4M shares
of 49.6M outstanding shares and own 59.22% of the company stock.
Largest 10 shareholders include ACORN CAPITAL ADVISORS, LLC (3.94M shares), BlackRock, Inc. (3.82M shares), VANGUARD GROUP INC (3.64M shares), ACADIAN ASSET MANAGEMENT LLC (1.97M shares), MILLENNIUM MANAGEMENT LLC (1.89M shares), RENAISSANCE TECHNOLOGIES LLC (1.76M shares), Eversept Partners, LP (996K shares), AMERICAN CENTURY COMPANIES INC (948K shares), GEODE CAPITAL MANAGEMENT, LLC (919K shares), and DIMENSIONAL FUND ADVISORS LP (864K shares).
This table shows the top 111 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.